Tarlatamab Receives Accelerated Approval for Extensive-Stage

The FDA has approved tarlatamab, a novel bispecific T-cell engager, to treat patients with extensive-cell small cell lung cancer (SCLC).

Related Keywords

Jay Bradner , Davidp Carbone , Laurie Fenton Ambrose , National Cancer Institute , James Thoracic Oncology Center , Ohio State University Medical Center , Amgen , Ohio State University Medical , New England Journal , Boxed Warning ,